NeuroSigma Announces U.S. Commercial Launch of Second-Generation Monarch® eTNS System for Pediatric ADHD

RegulatoryapprovedMonarch® eTNS SystemPositive

AI Analysis

Summary

NeuroSigma announced the U.S. commercial launch of its second-generation Monarch® eTNS System, an FDA-cleared non-drug treatment for pediatric ADHD. This represents a regulatory milestone and market entry for the bioelectronic medical device.

Outcome Details

Second-generation Monarch® eTNS System cleared by FDA as non-drug treatment for pediatric ADHD

Importance:6/10

Sentiment:

0.75

FDA approvalmedical devicepediatric ADHDcommercial launchnon-drug treatment

Related Companies

$GBIO $MDCE

Read the original article

Published by GlobeNewswire Clinical Studies on July 21, 2026 1:00 PM

Read Original